Summary of Key Information:
Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing: Outcome of Board Meeting under SEBI LODR Regulations
Audit Opinion:
Limited Review Report - Clean opinion with emphasis of matter regarding income tax proceedings
Key Financial Highlights [INR Million]:
Standalone Results:
Revenue from Operations: ₹2,106.61 (Q1 FY27) vs ₹1,756.15 (Q1 FY26) - 20% YoY increase
Total Income: ₹2,178.70 (Q1 FY27) vs ₹1,796.13 (Q1 FY26)
Net Profit: ₹158.20 (Q1 FY27) vs ₹195.62 (Q1 FY26) - 19% YoY decrease
EPS: ₹4.88 (Basic) and ₹4.82 (Diluted) for Q1 FY27
Other Equity: Not specified for quarter, ₹9,756.92 for year ended March 31, 2026
Consolidated Results:
Revenue from Operations: ₹2,710.63 (Q1 FY27) vs ₹2,212.20 (Q1 FY26) - 23% YoY increase
Total Income: ₹2,710.63 (Q1 FY27) vs ₹2,212.20 (Q1 FY26)
Net Profit: ₹165.51 (Q1 FY27) vs ₹205.20 (Q1 FY26) - 19% YoY decrease
EPS: ₹5.10 (Basic) and ₹5.04 (Diluted) for Q1 FY27
Other Equity: ₹9,641.69 for year ended March 31, 2026
Segment-wise Performance:
The Group has a single reportable segment - diagnostic services in radiology and pathology services. The group derives entire revenue from external customers in India and has entire assets located in India. The group has two major external customers which account for 10% or more of group's revenues.
Corporate Actions:
Dividend: Final dividend of ₹2.00 per share (Face Value ₹5) recommended for FY 2024-25
Record Date: Friday, September 18, 2026
Book Closure: September 19, 2026 to September 28, 2026 (both days inclusive)
AGM Date: Monday, September 28, 2026 at 11:00 Hrs (IST) in Physical Mode
Preferential Issue: Approval for issuance of 16,21,000 share warrants to Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited (Promoter and Promoter Group) at an issue price which would be higher of: (i) The floor price as on the relevant date in future as determined in accordance with SEBI ICDR Regulations, 2018, or (ii) ₹565
Post-allotment shareholding of promoters: Mr. Rajendra Mutha would increase from 24.75% to 23.79%, Krsna Diagnostics (Mumbai) Private Limited would increase from 2.36% to 6.78% (assuming full subscription)
Other Significant Information:
The results include financial results for quarter ended March 31, 2026 which are balancing results between audited results for full year ended March 31, 2026 and published year-to-date results for nine month period ended December 31, 2025.
Consolidation includes: 8 wholly-owned subsidiaries and 1 step-down associate (Apulki Healthcare KDMC Private Limited)